Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-08. Numbers and descriptions here follow the published literature rather than marketing material.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Cligosiban (INNTooltip International Nonproprietary Name; developmental code names IX-01 and PF-3274167) is an oxytocin receptor antagonist which is or was under development for the treatment of premature ejaculation. It is taken orally. The drug is a small molecule or non-peptide and is a potent, highly selective, and brain-penetrant antagonist of the oxytocin receptor. Cligosiban was originated by Pfizer and is under development by Ixchelsis and Chorus Group. As of December 2019, it is in phase 2 clinical trials. However, another source lists the drug's development as having been discontinued. The drug failed to show effectiveness in a phase 2b trial.
Wiskott–Aldrich syndrome (WAS) patients also present with eczema, autoimmune manifestations, recurrent bacterial infections, and lymphoma. In autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), autoimmunity and infections coexist: organ-specific autoimmune manifestations (e.g., hypoparathyroidism and adrenocortical failure) and chronic mucocutaneous candidiasis. Finally, IgA deficiency is sometimes associated with developing autoimmune and atopic phenomena.
=== Corrosion === Ammonium carbamate solutions are highly corrosive to metallic construction materials – even to resistant forms of stainless steel – especially in the hottest parts of the synthesis plant such as the stripper. Historically corrosion has been minimized (although not eliminated) by continuous injection of a small amount of oxygen (as air) into the plant to establish and maintain a passive oxide layer on exposed stainless steel surfaces. Highly corrosion resistant materials have been introduced to reduce the need for passivation oxygen, such as specialized duplex stainless steels in the 1990s, and zirconium or zirconium-clad titanium tubing in the 2000s.
== Research == A 2016 review found that reserpine reduced systolic blood pressure (SBP) by about 8 mmHg compared to placebo, and may be as effective at reducing SBP as other front-line hypertensive drugs, although more research is needed to determine a dose-specific safety profile.
Sources: en.wikipedia.org
== Research career and academic posts == After completing graduate school, Fenn's first job was with Monsanto, working in the Phosphate Division and producing polychlorinated biphenyls (PCBs). Fenn and his colleague James Mullen became disenchanted with the direction of work at Monsanto, and they resigned together in 1943. Fenn worked briefly at a small company named Sharples Chemicals that focused on the production of amyl chloride derivatives. In 1945, he joined Mullen at his new startup, Experiment, Inc, focusing on research and development. Fenn's first publication came in 1949 as a result of his work with Mullen. That this publication came ten years after he completed graduate school made Fenn somewhat of a rarity amongst academics. In 1952, Fenn moved to Princeton University as Director of Project SQUID, a program to support research related to jet propulsion that was funded by the Office of Naval Research. During this period, Fenn started his work developing supersonic atomic and molecular beam sources, which are now widely used in chemical physics research. After working with Project SQUID, Fenn returned to Yale University in 1967. He held a joint appointment in the chemistry and engineering departments until 1987, conducting much of his research in Mason Laboratory. In 1987, Fenn had reached Yale's mandatory retirement age. He became a professor emeritus, entitling him to office space at the university, but costing him most of his laboratory space and research assistants.
Eventually the funk project broke up, and in 1987 Staley joined Cantrell's band on a full-time basis. Two weeks after the band's formation, they were playing a gig at Washington State University, trying to fill in a 40-minute set with a couple of original songs along with Hanoi Rocks and David Bowie covers. The band played a couple of gigs in clubs around the Pacific Northwest, calling themselves different monikers, including Diamond Lie, the name of Cantrell's previous band, and "Fuck", before eventually adopting the name that Staley's previous band had initially flirted with, Alice in Chains. Staley contacted his former bandmates and asked for permission to use the name. Nick Pollock was not particularly thrilled about it at the time, and thought he should come up with a different name; both he and James Bergstrom ultimately gave Staley their blessing to use the name.
By 1982, the perceived passivity of the FARC, together with the relative success of the government's efforts against the M-19 and the ELN, enabled the administration of the Liberal Party's Julio César Turbay Ayala (1978–82) to lift a state-of-siege decree that had been in effect, on and off, for most of the previous 30 years. Under the latest such decree, President Turbay had implemented security policies that, though of some military value against the M-19 in particular, were considered highly questionable both inside and outside Colombian circles due to numerous accusations of military human rights abuses against suspects and captured guerrillas. Citizen exhaustion due to the conflict's newfound intensity led to the election of President Belisario Betancur (1982–1986), a Conservative, with 47% of the popular vote. Betancur directed peace feelers at all the insurgents and negotiated a 1984 cease-fire with the FARC at La Uribe, Meta, after a 1982 release of many guerrillas imprisoned during the previous effort to overpower them. A truce was also arranged with the M-19. The ELN, however, rejected any negotiations and continued to rebuild through the use of extortion and threats, in particular against oil companies of European and U.S. origin. At the same time as these developments, the growing illegal drug trade was becoming increasingly important to all participants in the Colombian conflict. Guerrillas and newly wealthy drug lords had mutually uneven relations, and numerous incidents occurred between them.
Sources: en.wikipedia.org
=== Research === A major source of bubble instability is when a wide variety of sizes of bubbles are created, gases in smaller bubbles diffuses or disperses into larger bubbles. This is due to their differing Laplace pressures. As of 2023, technologies to control bubble size, distribution and movement were difficult to employ during production. "Advanced" research was underway, including by companies such as Nestlé. In 2013, scientists released the results of experimental research on the impact of phospholipids on aerating cocoa butter. The research found that although all phospholipids tested made cocoa butter foam more, the foam's stability varied by type of phospholipid. The final cocoa butter was also observed to be more stable when the process was undertaken at lower temperatures.
B'Tselem also argues that the restrictions on ill, wounded and pregnant Palestinians seeking acute medical care is in contravention of international law that states that medical professionals and the sick must be granted open passage. While Israeli Supreme Court has deemed the measures acceptable for security reasons, Haaretz's Amira Hass argues this policy defies one of the principles of the Oslo Accords, which states that Gaza and the West Bank constitute a single geographic unit. Strained intercommunal relations in Northern Ireland between Irish Catholics and the descendants of Protestant settlers from England and Scotland have resulted in de facto internal checkpoints. The peace lines are an internal border security measure to separate predominantly republican and nationalist Catholic neighbourhoods from predominantly loyalist and unionist Protestant neighbourhoods. They have been in place in some form or another since the end of The Troubles in 1998, with the Good Friday Agreement. The majority of peace walls are located in Belfast, but they also exist in Derry, Portadown, and Lurgan, with more than 32 kilometres (20 miles) of walls in Northern Ireland. The peace lines range in length from a few hundred metres to over 5 kilometres. They may be made of iron, brick, steel, or a combination of the three and are up to 8 metres (26 feet) high. Some have gates in them (sometimes staffed by police) that allow passage during daylight but are closed at night.
== Personal life == Kahn is married to Susan Becker Kahn, also formerly of Louisville. They have two children. Stacy Anne Kahn is a pediatric gastroenterologist at the Boston Children's Hospital. Jeffrey Adam Kahn is managing partner of Continuum Search based in Denver, Colorado. His brother Arnold Kahn was emeritus professor of developmental biology of the University of California San Francisco.
In early August, the division was transferred to East Prussia from Army Group South Ukraine. Over the next months, Großdeutschland was involved in heavy fighting in both East Prussia – including a counter-attack on Wilkowischken – and the Baltic States, suffering high casualties in both men and materiel. The division was nearly destroyed during the battles in the Memel bridgehead.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.